A systematic review of emerging technologies to enhance the treatment of ovarian cancer

References

• Abriata JP, Turatti RC, Luiz MT, Raspantini GL, Tofani LB, do Amaral RLF, Swiech K, Marcato PD, Marchetti JM. 2019. Development, characterization and biological in vitro assays of paclitaxel-loaded PCL polymeric nanoparticles. Mater Sci Eng C Mater Biol Appl. 96:347–355. doi: 10.1016/j.msec.2018.11.035.
   PubMed Web of Science ®Google Scholar
• Adepu S, Ramakrishna S. 2021. Controlled drug delivery systems: current status and future directions. Molecules. 26(19):5905. doi: 10.3390/molecules26195905.
   PubMed Web of Science ®Google Scholar
• Ak G, Yilmaz H, Güneş A, Hamarat Sanlier S. 2018. In vitro and in vivo evaluation of folate receptor-targeted a novel magnetic drug delivery system for ovarian cancer therapy. Artif Cells Nanomed Biotechnol. 46(Suppl 1):926–937. doi: 10.1080/21691401.2018.1439838.
   PubMedGoogle Scholar
• Amoozgar Z, Wang L, Brandstoetter T, Wallis SS, Wilson EM, Goldberg MS. 2014. Dual-layer surface coating of PLGA-based nanoparticles provides slow-release drug delivery to achieve metronomic therapy in a paclitaxel-resistant murine ovarian cancer model. Biomacromolecules. 15(11):4187–4194. doi: 10.1021/bm5011933.
   PubMed Web of Science ®Google Scholar
• Aqil F, Jeyabalan J, Agrawal AK, Kyakulaga AH, Munagala R, Parker L, Gupta RC. 2017. Exosomal delivery of berry anthocyanidins for the management of ovarian cancer. Food Funct. 8(11):4100–4107. doi: 10.1039/c7fo00882a.
   PubMed Web of Science ®Google Scholar
• Arora HC, Jensen MP, Yuan Y, Wu A, Vogt S, Paunesku T, Woloschak GE. 2012. Nanocarriers enhance Doxorubicin uptake in drug-resistant ovarian cancer cells [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Cancer Res. 72(3):769–778. doi: 10.1158/0008-5472.CAN-11-2890.
   PubMed Web of Science ®Google Scholar
• Asoodeh A, Ghorani-Azam A, Chamani J. 2012. Identification and characterization of novel antibacterial peptides from skin secretions of Euphlyctis cyanophlyctis. Int J Pept Res Ther. 18(2):107–115. doi: 10.1007/s10989-011-9284-6.
   Web of Science ®Google Scholar
• Asoodeh A, Sepahi S, Ghorani-Azam A. 2014. Purification and modeling amphipathic alpha helical antimicrobial peptides from skin secretions of Euphlyctis cyanophlyctis. Chem Biol Drug Des. 83(4):411–417. doi: 10.1111/cbdd.12256.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Anjum MM, Patel KK. 2022. Gemcitabine cationic polymeric nanoparticles against ovarian cancer: formulation, characterization, and targeted drug delivery. Drug Deliv. 29(1):1060–1074. doi: 10.1080/10717544.2022.2058645.
   PubMed Web of Science ®Google Scholar
• Brunetti J, Pillozzi S, Falciani C, Depau L, Tenori E, Scali S, Lozzi L, Pini A, Arcangeli A, Menichetti S, et al. 2015. Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drug. Sci Rep. 5:17736. doi: 10.1038/srep17736.
   PubMed Web of Science ®Google Scholar
• Byeon Y, Lee JW, Choi WS, Won JE, Kim GH, Kim MG, Wi TI, Lee JM, Kang TH, Jung ID, et al. 2018. CD44-targeting PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer. Cancer Res. 78(21):6247–6256. doi: 10.1158/0008-5472.CAN-17-3871.
   PubMed Web of Science ®Google Scholar
• Chahibi Y, Akyildiz IF, Balasubramaniam S, Koucheryavy Y. 2015. Molecular communication modeling of antibody-mediated drug delivery systems. IEEE Trans Biomed Eng. 62(7):1683–1695. doi: 10.1109/TBME.2015.2400631.
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu M, Guo Y, Tu K, Wu W, Wang J, Tong X, Wu W, Qi L, Shi D. 2017. Targeted chimera delivery to ovarian cancer cells by heterogeneous gold magnetic nanoparticle. Nanotechnology. 28(2):025101. doi: 10.1088/0957-4484/28/2/025101.
   PubMed Web of Science ®Google Scholar
• Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, et al. 2017. Dual-targeting nanoparticles for in vivo delivery of suicide genes to chemotherapy-resistant ovarian cancer cells [Research Support, Non-U.S. Gov’t Research Support, N.I.H., Extramural]. Mol Cancer Ther. 16(2):323–333. doi: 10.1158/1535-7163.MCT-16-0501.
   PubMed Web of Science ®Google Scholar
• Coelho JF, Ferreira PC, Alves P, Cordeiro R, Fonseca AC, Gois JR, Gil MH. 2010. Drug delivery systems: advanced technologies potentially applicable in personalized treatments. EPMA J. 1(1):164–209. doi: 10.1007/s13167-010-0001-x.
   PubMedGoogle Scholar
• Desale SS, Soni KS, Romanova S, Cohen SM, Bronich TK. 2015. Targeted delivery of platinum-taxane combination therapy in ovarian cancer [Research Support, N.I.H., Extramural]. J Control Release. 220(Pt B):651–659. doi: 10.1016/j.jconrel.2015.09.007.
   PubMed Web of Science ®Google Scholar
• Deshpande P, Jhaveri A, Pattni B, Biswas S, Torchilin V. 2018. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer. Drug Deliv. 25(1):517–532. doi: 10.1080/10717544.2018.1435747.
   PubMed Web of Science ®Google Scholar
• Dharap SS, Qiu B, Williams GC, Sinko P, Stein S, Minko T. 2003. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides [Research Support, Non-U.S. Gov’t]. J Control Release. 91(1–2):61–73. doi: 10.1016/s0168-3659(03)00209-8.
   PubMed Web of Science ®Google Scholar
• Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, Zeb A. 2017. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors [Review]. Int J Nanomedicine. 12:7291–7309. doi: 10.2147/IJN.S146315.
   PubMed Web of Science ®Google Scholar
• Duska LR, Krasner CN, O'Malley DM, Hays JL, Modesitt SC, Mathews CA, Moore KN, Thaker PH, Miller A, Purdy C, et al. 2021. A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer [Clinical Trial, Phase I Clinical Trial, Phase II Research Support, Non-U.S. Gov’t]. Gynecol Oncol. 160(3):688–695. doi: 10.1016/j.ygyno.2020.12.025.
   PubMed Web of Science ®Google Scholar
• Fan L, Chen J, Zhang X, Liu Y, Xu C. 2014. Follicle-stimulating hormone polypeptide modified nanoparticle drug delivery system in the treatment of lymphatic metastasis during ovarian carcinoma therapy. Gynecol Oncol. 135(1):125–132. doi: 10.1016/j.ygyno.2014.06.030.
   PubMed Web of Science ®Google Scholar
• Florinas S, Kim J, Nam K, Janat-Amsbury MM, Kim SW. 2014. Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment [Research Support, N.I.H., Extramural]. J Control Release. 183:1–8. doi: 10.1016/j.jconrel.2014.03.025.
   PubMed Web of Science ®Google Scholar
• Frank D, Indermun S, Govender M, Kumar P, Choonara YE, Du Toit LC, Pillay V. 2019. Antineoplastic nano-lipobubbles for passively targeted ovarian cancer therapy. Colloids Surf B. 177:160–168. doi: 10.1016/j.colsurfb.2019.01.049.
   PubMed Web of Science ®Google Scholar
• Fujiwara S, Nawa A, Luo C, Kamakura M, Goshima F, Kondo C, Kiyono T, Kikkawa F, Nishiyama Y. 2011. Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer [Research Support, Non-U.S. Gov’t]. Cancer Gene Ther. 18(2):77–86. doi: 10.1038/cgt.2010.53.
   PubMed Web of Science ®Google Scholar
• Ghafoorianfar S, Ghorani-Azam A, Mohajeri SA, Farzin D. 2020. Efficiency of nanoparticles for treatment of ocular infections: systematic literature review. J Drug Deliv Sci Technol. 57:101765. doi: 10.1016/j.jddst.2020.101765.
   Web of Science ®Google Scholar
• Ghareghomi S, Ahmadian S, Zarghami N, Hemmati S. 2021. hTERT-molecular targeted therapy of ovarian cancer cells via folate-functionalized PLGA nanoparticles co-loaded with MNPs/siRNA/wortmannin. Life Sci. 277:119621. doi: 10.1016/j.lfs.2021.119621.
   PubMed Web of Science ®Google Scholar
• Ghassami E, Varshosaz J, Jahanian-Najafabadi A, Minaiyan M, Rajabi P, Hayati E. 2018. Pharmacokinetics and in vitro/in vivo antitumor efficacy of aptamer-targeted Ecoflex((R)) nanoparticles for docetaxel delivery in ovarian cancer. Int J Nanomedicine. 13:493–504. doi: 10.2147/IJN.S152474.
   PubMed Web of Science ®Google Scholar
• Ghorani-Azam A, Balali-Mood M, Aryan E, Karimi G, Riahi-Zanjani B. 2018. Effect of amino acid substitution on biological activity of cyanophlyctin-β and brevinin-2R. J Mol Struct. 1158:14–18. doi: 10.1016/j.molstruc.2018.01.015.
   Web of Science ®Google Scholar
• Goldberg MS, Xing D, Ren Y, Orsulic S, Bhatia SN, Sharp PA. 2011. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Proc Natl Acad Sci U S A. 108(2):745–750. doi: 10.1073/pnas.1016538108.
   PubMed Web of Science ®Google Scholar
• Guduru R, Liang P, Runowicz C, Nair M, Atluri V, Khizroev S. 2013. Magneto-electric nanoparticles to enable field-controlled high-specificity drug delivery to eradicate ovarian cancer cells [Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, Non-P.H.S.]. Sci Rep. 3:2953. doi: 10.1038/srep02953.
   PubMed Web of Science ®Google Scholar
• Guo L, Zhang Y, Yang Z, Peng H, Wei R, Wang C, Feng M. 2019. Tunneling nanotubular expressways for ultrafast and accurate M1 macrophage delivery of anticancer drugs to metastatic ovarian carcinoma [Research Support, Non-U.S. Gov’t]. ACS Nano. 13(2):1078–1096. doi: 10.1021/acsnano.8b08872.
   PubMed Web of Science ®Google Scholar
• Guo T, Zhu Y, Yue M, Wang F, Li Z, Lin M. 2022. The therapeutic effects of DDP/CD44-shRNA nanoliposomes in AMF on ovarian cancer. Front Oncol. 12:811783. doi: 10.3389/fonc.2022.811783.
   PubMed Web of Science ®Google Scholar
• Guo X, Fang Z, Zhang M, Yang D, Wang S, Liu K. 2020. A co-delivery system of curcumin and p53 for enhancing the sensitivity of drug-resistant ovarian cancer cells to cisplatin. Molecules. 25(11):2621. doi: 10.3390/molecules25112621.
   PubMed Web of Science ®Google Scholar
• Guo X, Guo N, Zhao J, Cai Y. 2017. Active targeting co-delivery system based on hollow mesoporous silica nanoparticles for antitumor therapy in ovarian cancer stem-like cells. Oncol Rep. 38(3):1442–1450. doi: 10.3892/or.2017.5829.
   PubMed Web of Science ®Google Scholar
• Guo X, Mei J, Zhang C. 2020. Development of drug dual-carriers delivery system with mitochondria-targeted and pH/heat responsive capacity for synergistic photothermal-chemotherapy of ovarian cancer. Int J Nanomedicine. 15:301–313. doi: 10.2147/IJN.S226517.
   PubMed Web of Science ®Google Scholar
• He C, Poon C, Chan C, Yamada SD, Lin W. 2016. Nanoscale Coordination Polymers Codeliver Chemotherapeutics And siRNAs to eradicate tumors of cisplatin-resistant ovarian cancer [Research Support, N.I.H., Extramural]. J Am Chem Soc. 138(18):6010–6019. doi: 10.1021/jacs.6b02486.
   PubMed Web of Science ®Google Scholar
• Hu Y, Ran M, Wang B, Lin Y, Cheng Y, Zheng S. 2020. Co-delivery of docetaxel and curcumin via nanomicelles for enhancing anti-ovarian cancer treatment. Int J Nanomedicine. 15:9703–9715. doi: 10.2147/IJN.S274083.
   PubMed Web of Science ®Google Scholar
• Huang YH, Peng W, Furuuchi N, Gerhart J, Rhodes K, Mukherjee N, Jimbo M, Gonye GE, Brody JR, Getts RC, et al. 2016. Delivery of therapeutics targeting the mRNA-binding protein HuR using 3DNA nanocarriers suppresses ovarian tumor growth [Research Support, Non-U.S. Gov’t]. Cancer Res. 76(6):1549–1559. doi: 10.1158/0008-5472.CAN-15-2073.
   PubMed Web of Science ®Google Scholar
• Jang SH, Choi SJ, Oh JH, Chae SW, Nam K, Park JS, Lee HJ. 2011. Nonviral gene delivery to human ovarian cancer cells using arginine-grafted PAMAM dendrimer [Research Support, Non-U.S. Gov’t]. Drug Dev Ind Pharm. 37(1):41–46. doi: 10.3109/03639045.2010.489563.
   PubMed Web of Science ®Google Scholar
• Javid A, Ahmadian S, Saboury AA, Kalantar SM, Rezaei-Zarchi S, Shahzad S. 2014. Biocompatible APTES-PEG modified magnetite nanoparticles: effective carriers of antineoplastic agents to ovarian cancer [Research Support, Non-U.S. Gov’t]. Appl Biochem Biotechnol. 173(1):36–54. doi: 10.1007/s12010-014-0740-6.
   PubMed Web of Science ®Google Scholar
• Kala S, Mak AS, Liu X, Posocco P, Pricl S, Peng L, Wong AS. 2014. Combination of dendrimer-nanovector-mediated small interfering RNA delivery to target Akt with the clinical anticancer drug paclitaxel for effective and potent anticancer activity in treating ovarian cancer [Research Support, Non-U.S. Gov’t]. J Med Chem. 57(6):2634–2642. doi: 10.1021/jm401907z.
   PubMed Web of Science ®Google Scholar
• Kalaydina RV, Bajwa K, Qorri B, Decarlo A, Szewczuk MR. 2018. Recent advances in “smart” delivery systems for extended drug release in cancer therapy [Review]. Int J Nanomedicine. 13:4727–4745. doi: 10.2147/IJN.S168053.
   PubMed Web of Science ®Google Scholar
• Kaye SB, Colombo N, Monk BJ, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Vergote I, et al. 2011. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Ann Oncol. 22(1):49–58. doi: 10.1093/annonc/mdq353.
   PubMed Web of Science ®Google Scholar
• Khames A, Khaleel MA, El-Badawy MF, El-Nezhawy AOH. 2019. Natamycin solid lipid nanoparticles – sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: preparation and optimization. Int J Nanomedicine. 14:2515–2531. doi: 10.2147/IJN.S190502.
   PubMed Web of Science ®Google Scholar
• Kim GH, Won JE, Byeon Y, Kim MG, Wi TI, Lee JM, Park YY, Lee JW, Kang TH, Jung ID, et al. 2018. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. Drug Deliv. 25(1):1394–1402. doi: 10.1080/10717544.2018.1480672.
   PubMed Web of Science ®Google Scholar
• Kim Y, Pourgholami MH, Morris DL, Stenzel MH. 2011. An optimized RGD-decorated micellar drug delivery system for albendazole for the treatment of ovarian cancer: from RAFT polymer synthesis to cellular uptake [Research Support, Non-U.S. Gov’t]. Macromol Biosci. 11(2):219–233. doi: 10.1002/mabi.201000293.
   PubMed Web of Science ®Google Scholar
• Klajnert B, Bryszewska M. 2001. Dendrimers: properties and applications [Review]. Acta Biochim Pol. 48(1):199–208. doi: 10.18388/abp.2001_5127.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Sawada K, Miyamoto M, Shimizu A, Yamamoto M, Kinose Y, Nakamura K, Kawano M, Kodama M, Hashimoto K, et al. 2020. Exploring the potential of engineered exosomes as delivery systems for tumor-suppressor microRNA replacement therapy in ovarian cancer [Research Support, Non-U.S. Gov’t]. Biochem Biophys Res Commun. 527(1):153–161. doi: 10.1016/j.bbrc.2020.04.076.
   PubMed Web of Science ®Google Scholar
• Kulhari H, Pooja D, Kota R, Reddy TS, Tabor RF, Shukla R, Adams DJ, Sistla R, Bansal V. 2016. Cyclic RGDfK peptide functionalized polymeric nanocarriers for targeting gemcitabine to ovarian cancer cells [Research Support, Non-U.S. Gov’t]. Mol Pharm. 13(5):1491–1500. doi: 10.1021/acs.molpharmaceut.5b00935.
   PubMedGoogle Scholar
• Kumari M, Prasad S, Fruk L, Parshad B. 2021. Polyglycerol-based hydrogels and nanogels: from synthesis to applications [Review]. Future Med Chem. 13(4):419–438. doi: 10.4155/fmc-2020-0205.
   PubMed Web of Science ®Google Scholar
• Lee J, Ahn HJ. 2018. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery carrier for ovarian cancer therapy [Research Support, Non-U.S. Gov’t]. Biochem Biophys Res Commun. 503(3):1716–1722. doi: 10.1016/j.bbrc.2018.07.104.
   PubMed Web of Science ®Google Scholar
• Li S, Li X, Ding J, Han L, Guo X. 2019. Anti-tumor efficacy of folate modified PLGA-based nanoparticles for the co-delivery of drugs in ovarian cancer. Drug Des Devel Ther. 13:1271–1280. doi: 10.2147/DDDT.S195493.
   PubMed Web of Science ®Google Scholar
• Lin CJ, Kuan CH, Wang LW, Wu HC, Chen Y, Chang CW, Huang RY, Wang TW. 2016. Integrated self-assembling drug delivery system possessing dual responsive and active targeting for orthotopic ovarian cancer theranostics [Research Support, Non-U.S. Gov’t]. Biomaterials. 90:12–26. doi: 10.1016/j.biomaterials.2016.03.005.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ng Y, Toh MR, Chiu GNC. 2015. Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer [Research Support, Non-U.S. Gov’t]. J Control Release. 220(Pt A):438–446. doi: 10.1016/j.jconrel.2015.11.004.
   PubMedGoogle Scholar
• Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK. 2009. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. Mol Oncol. 3(2):97–137. doi: 10.1016/j.molonc.2009.02.004.
   PubMed Web of Science ®Google Scholar
• Mohseni S, Aghayan M, Ghorani-Azam A, Behdani M, Asoodeh A. 2014. Evaluation of antibacterial properties of barium zirconate titanate (BZT) nanoparticle. Braz J Microbiol. 45(4):1393–1399. doi: 10.1590/s1517-83822014000400033.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita AS, Nieto A, Park YC, Cheng PS, Li W, et al. 2015. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Ann Oncol. 26(5):914–920. doi: 10.1093/annonc/mdv071.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM. 2012. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial]. Eur J Cancer. 48(15):2361–2368. doi: 10.1016/j.ejca.2012.04.001.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog TJ, Wang G, Triantos S, Maul S, Knoblauch R, McGowan T, Shalaby WSW, Coleman RL. 2020. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Gynecol Oncol. 156(3):535–544. doi: 10.1016/j.ygyno.2019.12.043.
   PubMed Web of Science ®Google Scholar
• Naseri N, Valizadeh H, Zakeri-Milani P. 2015. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application [Review]. Adv Pharm Bull. 5(3):305–313. doi: 10.15171/apb.2015.043.
   PubMed Web of Science ®Google Scholar
• Niu X, Gao Z, Qi S, Su L, Yang N, Luan X, Li J, Zhang Q, An Y, Zhang S. 2018. Macropinocytosis activated by oncogenic Dbl enables specific targeted delivery of Tat/pDNA nano-complexes into ovarian cancer cells. Int J Nanomedicine. 13:4895–4911. doi: 10.2147/IJN.S171361.
   PubMed Web of Science ®Google Scholar
• Nukolova NV, Oberoi HS, Zhao Y, Chekhonin VP, Kabanov AV, Bronich TK. 2013. LHRH-targeted nanogels as a delivery system for cisplatin to ovarian cancer [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Mol Pharm. 10(10):3913–3921. doi: 10.1021/mp4003688.
   PubMedGoogle Scholar
• Oda K, Ikeda Y, Kashiyama T, Miyasaka A, Inaba K, Fukuda T, Asada K, Sone K, Wada-Hiraike O, Kawana K, et al. 2016. Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies. J Obstet Gynaecol Res. 42(7):757–762. doi: 10.1111/jog.13018.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. BMJ. 372:n71. doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Pan D, She W, Guo C, Luo K, Yi Q, Gu Z. 2014. PEGylated dendritic diaminocyclohexyl-platinum (II) conjugates as pH-responsive drug delivery vehicles with enhanced tumor accumulation and antitumor efficacy [Research Support, Non-U.S. Gov’t]. Biomaterials. 35(38):10080–10092. doi: 10.1016/j.biomaterials.2014.09.006.
   PubMed Web of Science ®Google Scholar
• Patel NR, Piroyan A, Ganta S, Morse AB, Candiloro KM, Solon AL, Nack AH, Galati CA, Bora C, Maglaty MA, et al. 2018. In vitro and in vivo evaluation of a novel folate-targeted theranostic nanoemulsion of docetaxel for imaging and improved anticancer activity against ovarian cancers [Research Support, N.I.H., Extramural]. Cancer Biol Ther. 19(7):554–564. doi: 10.1080/15384047.2017.1395118.
   PubMed Web of Science ®Google Scholar
• Pattni BS, Nagelli SG, Aryasomayajula B, Deshpande PP, Kulkarni A, Hartner WC, Thakur G, Degterev A, Torchilin VP. 2016. Targeting of micelles and liposomes loaded with the pro-apoptotic drug, NCL-240, into NCI/ADR-RES cells in a 3D spheroid model [Research Support, N.I.H., Extramural]. Pharm Res. 33(10):2540–2551. doi: 10.1007/s11095-016-1978-1.
   PubMed Web of Science ®Google Scholar
• Peng Y, Chen L, Ye S, Kang Y, Liu J, Zeng S, Yu L. 2020. Research and development of drug delivery systems based on drug transporter and nano-formulation [Review]. Asian J Pharm Sci. 15(2):220–236. doi: 10.1016/j.ajps.2020.02.004.
   PubMed Web of Science ®Google Scholar
• Pi F, Zhang H, Li H, Thiviyanathan V, Gorenstein DG, Sood AK, Guo P. 2017. RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Nanomedicine. 13(3):1183–1193. doi: 10.1016/j.nano.2016.11.015.
   PubMed Web of Science ®Google Scholar
• Pignata S, Scambia G, Villanucci A, Naglieri E, Ibarbia MA, Brusa F, Bourgeois H, Sorio R, Casado A, Reichert D, et al. 2021. A European, observational, prospective trial of trabectedin plus pegylated liposomal doxorubicin in patients with platinum-sensitive ovarian cancer [Clinical Trial, Phase IV Observational Study Research Support, Non-U.S. Gov’t]. Oncologist. 26(4):e658–e668. doi: 10.1002/onco.13630.
   PubMed Web of Science ®Google Scholar
• Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, et al. 2011. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Ann Oncol. 22(1):39–48. doi: 10.1093/annonc/mdq352.
   PubMed Web of Science ®Google Scholar
• Purushothaman K, Uma P, Begum KMMS. 2020. Magnetic casein-CaFe2O4 nanohybrid carrier conjugated with progesterone for enhanced cytotoxicity of citrus peel derived hesperidin drug towards breast and ovarian cancer. Int J Biol Macromol. 151:293–304. doi: 10.1016/j.ijbiomac.2020.02.172.
   PubMed Web of Science ®Google Scholar
• Reid BM, Permuth JB, Sellers TA. 2017. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 14(1):9–32.
   PubMed Web of Science ®Google Scholar
• Riahi-Zanjani B, Balali-Mood M, Asoodeh A, Es’haghi Z, Ghorani-Azam A. 2019. Potential application of amino acids in analytical toxicology. Talanta. 197:168–174. doi: 10.1016/j.talanta.2019.01.019.
   PubMed Web of Science ®Google Scholar
• Riahi-Zanjani B, Balali-Mood M, Es’haghi Z, Asoodeh A, Ghorani-Azam A. 2019. Molecular modeling and experimental study of a new peptide-based microextraction fiber for preconcentrating morphine in urine samples. J Mol Model. 25(3) doi: 10.1007/s00894-019-3925-7.
   PubMed Web of Science ®Google Scholar
• Ritskes-Hoitinga M, Leenaars M, Avey M, Rovers M, Scholten R. 2014. Systematic reviews of preclinical animal studies can make significant contributions to health care and more transparent translational medicine. Cochrane Database Syst Rev. 3:ED000078.
   Google Scholar
• Romani C, Cocco E, Bignotti E, Moratto D, Bugatti A, Todeschini P, Bandiera E, Tassi R, Zanotti L, Pecorelli S, et al. 2015. Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Oncotarget. 6(33):34617–34628. doi: 10.18632/oncotarget.5315.
   PubMedGoogle Scholar
• Satpathy M, Wang L, Zielinski RJ, Qian W, Wang YA, Mohs AM, Kairdolf BA, Ji X, Capala J, Lipowska M, et al. 2019. Targeted drug delivery and image-guided therapy of heterogeneous ovarian cancer using HER2-targeted theranostic nanoparticles [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Theranostics. 9(3):778–795. doi: 10.7150/thno.29964.
   PubMed Web of Science ®Google Scholar
• Saxena V, Hussain MD. 2013. Polymeric mixed micelles for delivery of curcumin to multidrug resistant ovarian cancer. J Biomed Nanotechnol. 9(7):1146–1154. doi: 10.1166/jbn.2013.1632.
   PubMed Web of Science ®Google Scholar
• Schirrmacher V. 2019. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment. Int J Oncol. 54(2):407–419. doi: 10.3892/ijo.2018.4661.
   PubMed Web of Science ®Google Scholar
• Shen W, Chen X, Luan J, Wang D, Yu L, Ding J. 2017. Sustained codelivery of cisplatin and paclitaxel via an injectable prodrug hydrogel for ovarian cancer treatment. ACS Appl Mater Interfaces. 9(46):40031–40046. doi: 10.1021/acsami.7b11998.
   PubMed Web of Science ®Google Scholar
• Sherje AP, Jadhav M, Dravyakar BR, Kadam D. 2018. Dendrimers: a versatile nanocarrier for drug delivery and targeting [Review]. Int J Pharm. 548(1):707–720. doi: 10.1016/j.ijpharm.2018.07.030.
   PubMed Web of Science ®Google Scholar
• Song H, Quan F, Yu Z, Zheng M, Ma Y, Xiao H, Ding F. 2019. Carboplatin prodrug conjugated Fe3O4 nanoparticles for magnetically targeted drug delivery in ovarian cancer cells [Research Support, Non-U.S. Gov’t]. J Mater Chem B. 7(3):433–442. doi: 10.1039/c8tb02574f.
   PubMed Web of Science ®Google Scholar
• Song KM, Lee S, Ban C. 2012. Aptamers and their biological applications [Research Support, Non-U.S. Gov’t Review]. Sensors. 12(1):612–631. doi: 10.3390/s120100612.
   PubMed Web of Science ®Google Scholar
• Soragni A, Janzen DM, Johnson LM, Lindgren AG, Thai-Quynh Nguyen A, Tiourin E, Soriaga AB, Lu J, Jiang L, Faull KF, et al. 2016. A designed inhibitor of p53 aggregation rescues p53 tumor suppression in ovarian carcinomas. Cancer Cell. 29(1):90–103. doi: 10.1016/j.ccell.2015.12.002.
   PubMed Web of Science ®Google Scholar
• Sun B, Taha MS, Ramsey B, Torregrosa-Allen S, Elzey BD, Yeo Y. 2016. Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals [Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, Non-P.H.S. Research Support, Non-U.S. Gov’t]. J Control Release. 235:91–98. doi: 10.1016/j.jconrel.2016.05.056.
   PubMed Web of Science ®Google Scholar
• Talekar M, Ganta S, Singh A, Amiji M, Kendall J, Denny WA, Garg S. 2012. Phosphatidylinositol 3-kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-apoptotic activity in ovarian cancer cells. Pharm Res. 29(10):2874–2886. doi: 10.1007/s11095-012-0793-6.
   PubMed Web of Science ®Google Scholar
• Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, Boehm KA, Williams A, Asmar L. 2009. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer [Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov’t]. J Clin Oncol. 27(9):1426–1431. doi: 10.1200/JCO.2008.18.9548.
   PubMed Web of Science ®Google Scholar
• Tiet P, Li J, Abidi W, Mooney R, Flores L, Aramburo S, Batalla-Covello J, Gonzaga J, Tsaturyan L, Kang Y, et al. 2019. Silica coated paclitaxel nanocrystals enable neural stem cell loading for treatment of ovarian cancer [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Bioconjug Chem. 30(5):1415–1424. doi: 10.1021/acs.bioconjchem.9b00160.
   PubMed Web of Science ®Google Scholar
• Tiwari H, Karki N, Pal M, Basak S, Verma RK, Bal R, Kandpal ND, Bisht G, Sahoo NG. 2019. Functionalized graphene oxide as a nanocarrier for dual drug delivery applications: the synergistic effect of quercetin and gefitinib against ovarian cancer cells. Colloids Surf B. 178:452–459. doi: 10.1016/j.colsurfb.2019.03.037.
   PubMed Web of Science ®Google Scholar
• van Luijk J, Bakker B, Rovers MM, Ritskes-Hoitinga M, de Vries RB, Leenaars M. 2014. Systematic reviews of animal studies; missing link in translational research? PLOS One. 9(3):e89981. doi: 10.1371/journal.pone.0089981.
   PubMed Web of Science ®Google Scholar
• Vandghanooni S, Eskandani M, Barar J, Omidi Y. 2020. Antisense LNA-loaded nanoparticles of star-shaped glucose-core PCL-PEG copolymer for enhanced inhibition of oncomiR-214 and nucleolin-mediated therapy of cisplatin-resistant ovarian cancer cells. Int J Pharm. 573:118729. doi: 10.1016/j.ijpharm.2019.118729.
   PubMedGoogle Scholar
• Vergote I, Bergfeldt K, Franquet A, Lisyanskaya AS, Bjermo H, Heldring N, Buyse M, Brize A. 2020. A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel [Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Gynecol Oncol. 156(2):293–300. doi: 10.1016/j.ygyno.2019.11.034.
   PubMed Web of Science ®Google Scholar
• Wang C, Li F, Zhang T, Yu M, Sun Y. 2022. Recent advances in anti-multidrug resistance for nano-drug delivery system. Drug Deliv. 29(1):1684–1697. doi: 10.1080/10717544.2022.2079771.
   PubMed Web of Science ®Google Scholar
• Wang C, Xia Y, Huo S, Shou D, Mei Q, Tang W, Li Y, Liu H, Zhou Y, Zhu B. 2020. Silencing of MEF2D by siRNA loaded selenium nanoparticles for ovarian cancer therapy. Int J Nanomedicine. 15:9759–9770. doi: 10.2147/IJN.S270441.
   PubMed Web of Science ®Google Scholar
• Wang J, Han S, Zhang Z, Wang J, Zhang G. 2021. Preparation and performance of chemotherapy drug-loaded graphene oxide-based nanosheets that target ovarian cancer cells via folate receptor mediation. J Biomed Nanotechnol. 17(5):960–970. doi: 10.1166/jbn.2021.3080.
   PubMed Web of Science ®Google Scholar
• Wang L, Jia E. 2016. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance. Drug Deliv. 23(5):1810–1817. doi: 10.3109/10717544.2015.1101792.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou J, Qiu L, Wang X, Chen L, Liu T, Di W. 2014. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells [Research Support, Non-U.S. Gov’t]. Biomaterials. 35(14):4297–4309. doi: 10.1016/j.biomaterials.2014.01.035.
   PubMed Web of Science ®Google Scholar
• Xiao K, Luo J, Fowler WL, Li Y, Lee JS, Xing L, Cheng RH, Wang L, Lam KS. 2009. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Biomaterials. 30(30):6006–6016. doi: 10.1016/j.biomaterials.2009.07.015.
   PubMed Web of Science ®Google Scholar
• Xue J, Li R, Gao D, Chen F, Xie H. 2020. CXCL12/CXCR4 axis-targeted dual-functional nano-drug delivery system against ovarian cancer. Int J Nanomedicine. 15:5701–5718. doi: 10.2147/IJN.S257527.
   PubMed Web of Science ®Google Scholar
• Yaşayan G, Mega Tiber P, Orun O, Alarçin E. 2020. Doxorubicin hydrochloride loaded nanotextured films as a novel drug delivery platform for ovarian cancer treatment. Pharm Dev Technol. 25(10):1289–1301. doi: 10.1080/10837450.2020.1823992.
   PubMed Web of Science ®Google Scholar
• Yellepeddi VK, Kumar A, Maher DM, Chauhan SC, Vangara KK, Palakurthi S. 2011. Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT [Research Support, N.I.H., Extramural]. Anticancer Res. 31(3):897–906.
   PubMed Web of Science ®Google Scholar
• Yuan MQ, Zhu F, Lou JY, Yuan WM, Fu L, Liu S, Zhang ZZ, Liu CY, He Q. 2014. The anti-tumoral efficacy of a docetaxel-loaded liposomal drug delivery system modified with transferrin for ovarian cancer [Research Support, Non-U.S. Gov’t]. Drug Res. 64(4):195–202. doi: 10.1055/s-0033-1355335.
   Google Scholar
• Zare-Zardini H, Ferdowsian F, Soltaninejad H, Ghorani Azam A, Soleymani S, Zare-Shehneh M, Mofidi M, Rafati R, Ebrahimi L. 2015. Application of nanotechnology in biomedicine: a major focus on cancer therapy. J Nano Res. 35:55–66. doi: 10.4028/www.scientific.net/JNanoR.35.55.
   Web of Science ®Google Scholar
• Zhai J, Luwor RB, Ahmed N, Escalona R, Tan FH, Fong C, Ratcliffe J, Scoble JA, Drummond CJ, Tran N. 2018. Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer. ACS Appl Mater Interfaces. 10(30):25174–25185. doi: 10.1021/acsami.8b08125.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guo J, Zhang XL, Li DP, Zhang TT, Gao FF, Liu NF, Sheng XG. 2015. Antibody fragment-armed mesoporous silica nanoparticles for the targeted delivery of bevacizumab in ovarian cancer cells [Research Support, Non-U.S. Gov’t]. Int J Pharm. 496(2):1026–1033. doi: 10.1016/j.ijpharm.2015.10.080.
   PubMedGoogle Scholar
• Zhang Y, Zhang P, Zhu T. 2019. Ovarian carcinoma biological nanotherapy: comparison of the advantages and drawbacks of lipid, polymeric, and hybrid nanoparticles for cisplatin delivery [Comparative Study]. Biomed Pharmacother. 109:475–483. doi: 10.1016/j.biopha.2018.10.158.
   PubMed Web of Science ®Google Scholar
• Zhao H, Li Q, Hong Z. 2016. Paclitaxel-loaded mixed micelles enhance ovarian cancer therapy through extracellular pH-triggered PEG detachment and endosomal escape. Mol Pharm. 13(7):2411–2422. doi: 10.1021/acs.molpharmaceut.6b00164.
   PubMedGoogle Scholar
• Zhao H, Wang JC, Sun QS, Luo CL, Zhang Q. 2009. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer [Evaluation Study Research Support, Non-U.S. Gov’t]. J Drug Target. 17(1):10–18. doi: 10.1080/10611860802368966.
   PubMed Web of Science ®Google Scholar
• Zheng W, Li M, Lin Y, Zhan X. 2018. Encapsulation of verapamil and doxorubicin by MPEG-PLA to reverse drug resistance in ovarian cancer. Biomed Pharmacother. 108:565–573. doi: 10.1016/j.biopha.2018.09.039.
   PubMed Web of Science ®Google Scholar
• Zhou HY, Hao JL, Wang S, Zheng Y, Zhang WS. 2013. Nanoparticles in the ocular drug delivery. Int J Ophthalmol. 6(3):390–396.
   PubMed Web of Science ®Google Scholar
• Zou S, Cao N, Cheng D, Zheng R, Wang J, Zhu K, Shuai X. 2012. Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin [Research Support, Non-U.S. Gov’t]. Int J Nanomedicine. 7:3823–3835. doi: 10.2147/IJN.S29328.
   PubMed Web of Science ®Google Scholar